IL155999A0 - Phenylethenyl or phenylethinyl derivatives as glutamate receptor antagonists - Google Patents
Phenylethenyl or phenylethinyl derivatives as glutamate receptor antagonistsInfo
- Publication number
- IL155999A0 IL155999A0 IL15599901A IL15599901A IL155999A0 IL 155999 A0 IL155999 A0 IL 155999A0 IL 15599901 A IL15599901 A IL 15599901A IL 15599901 A IL15599901 A IL 15599901A IL 155999 A0 IL155999 A0 IL 155999A0
- Authority
- IL
- Israel
- Prior art keywords
- phenylethinyl
- phenylethenyl
- derivatives
- receptor antagonists
- glutamate receptor
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
- C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
- C07D233/56—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, attached to ring carbon atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/34—Tobacco-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/36—Opioid-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/02—Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
- C07D209/04—Indoles; Hydrogenated indoles
- C07D209/10—Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
- C07D209/14—Radicals substituted by nitrogen atoms, not forming part of a nitro radical
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
- C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
- C07D233/64—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with substituted hydrocarbon radicals attached to ring carbon atoms, e.g. histidine
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
- C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
- C07D233/66—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D233/90—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
- C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
- C07D233/66—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D233/91—Nitro radicals
- C07D233/92—Nitro radicals attached in position 4 or 5
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
- C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
- C07D233/66—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D233/91—Nitro radicals
- C07D233/92—Nitro radicals attached in position 4 or 5
- C07D233/94—Nitro radicals attached in position 4 or 5 with hydrocarbon radicals, substituted by oxygen or sulfur atoms, attached to other ring members
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
- C07D513/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains three hetero rings
- C07D513/14—Ortho-condensed systems
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP00126615 | 2000-12-04 | ||
PCT/EP2001/013714 WO2002046166A1 (fr) | 2000-12-04 | 2001-11-26 | Derives phenylethenyle ou phenylethinyle servant d'antagonistes de recepteur de glutamate |
Publications (1)
Publication Number | Publication Date |
---|---|
IL155999A0 true IL155999A0 (en) | 2003-12-23 |
Family
ID=8170567
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
IL15599901A IL155999A0 (en) | 2000-12-04 | 2001-11-26 | Phenylethenyl or phenylethinyl derivatives as glutamate receptor antagonists |
IL155999A IL155999A (en) | 2000-12-04 | 2003-05-19 | PHENYLETHENYL OR PHENYLETHINYL DERIVATIVES, PROCESS FOR THEIR PREPARATION, PHARMACEUTICAL COMPOSITIONS COMPRISING SAME AND USE THEREOF FOR THE MANUFACTURE OF MEDICAMENTS FOR THE TREATMENT OR PREVENTION OF mGluR5 RECEPTOR MEDIATED DISORDERS |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
IL155999A IL155999A (en) | 2000-12-04 | 2003-05-19 | PHENYLETHENYL OR PHENYLETHINYL DERIVATIVES, PROCESS FOR THEIR PREPARATION, PHARMACEUTICAL COMPOSITIONS COMPRISING SAME AND USE THEREOF FOR THE MANUFACTURE OF MEDICAMENTS FOR THE TREATMENT OR PREVENTION OF mGluR5 RECEPTOR MEDIATED DISORDERS |
Country Status (32)
Country | Link |
---|---|
US (4) | US6706707B2 (fr) |
EP (1) | EP1349839B8 (fr) |
JP (2) | JP4077317B2 (fr) |
KR (1) | KR100515549B1 (fr) |
CN (1) | CN1257894C (fr) |
AR (1) | AR035401A1 (fr) |
AT (1) | ATE288898T1 (fr) |
AU (2) | AU2956702A (fr) |
BG (1) | BG107877A (fr) |
BR (1) | BR0115871A (fr) |
CA (1) | CA2430696C (fr) |
CZ (1) | CZ20031795A3 (fr) |
DE (1) | DE60108900T2 (fr) |
DK (1) | DK1349839T3 (fr) |
EC (1) | ECSP034640A (fr) |
ES (1) | ES2248410T3 (fr) |
HK (1) | HK1063318A1 (fr) |
HR (1) | HRP20030429A2 (fr) |
HU (1) | HUP0400570A3 (fr) |
IL (2) | IL155999A0 (fr) |
MA (1) | MA26971A1 (fr) |
MX (1) | MXPA03004862A (fr) |
NO (1) | NO324326B1 (fr) |
NZ (1) | NZ525917A (fr) |
PL (1) | PL366222A1 (fr) |
PT (1) | PT1349839E (fr) |
RS (1) | RS43903A (fr) |
RU (1) | RU2284323C9 (fr) |
SI (1) | SI1349839T1 (fr) |
SK (1) | SK8402003A3 (fr) |
WO (1) | WO2002046166A1 (fr) |
ZA (1) | ZA200303870B (fr) |
Families Citing this family (49)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB0128996D0 (en) * | 2001-12-04 | 2002-01-23 | Novartis Ag | Organic compounds |
WO2004014370A2 (fr) * | 2002-08-09 | 2004-02-19 | Astrazeneca Ab | Nouveaux composes |
RU2352568C9 (ru) | 2002-08-09 | 2009-06-27 | Астразенека Аб | [1,2,4]оксадиазолы (варианты), способ их получения, фармацевтическая композиция и способ ингибирования активации метаботропных глютаматных рецепторов-5 |
EP1581525A2 (fr) | 2002-08-09 | 2005-10-05 | AstraZeneca AB | Composes actif au niveau des recepteurs metabotropiques du glutamate |
ITMI20030151A1 (it) * | 2003-01-30 | 2004-07-31 | Recordati Ind Chimica E Farma Ceutica S P A | Uso di antagonisti selettivi del recettore mglu5 per il trattamento di disfunzioni neuromuscolari del tratto urinario inferiore. |
EP2028180A1 (fr) | 2003-03-04 | 2009-02-25 | ADDEX Pharma S.A. | Nouveaux dérivés d'aminopyridine en tant qu'antagonistes mGluR5 |
AU2004218115A1 (en) | 2003-03-07 | 2004-09-16 | Astellas Pharma Inc. | Nitrogenous heterocyclic derivative having 2,6-disubstituted styryl |
TWI292318B (en) | 2003-03-10 | 2008-01-11 | Hoffmann La Roche | Imidazol-4-yl-ethynyl-pyridine derivatives |
EP1611096A4 (fr) * | 2003-03-26 | 2007-08-29 | Merck & Co Inc | Modulateurs benzamide de recepteurs metabotropiques de glutamate |
US7531529B2 (en) | 2003-06-05 | 2009-05-12 | Roche Palo Alto Llc | Imidazole derivatives |
UA80888C2 (en) * | 2003-06-05 | 2007-11-12 | Hoffmann La Roche | Imidazole derivatives as glutmate receptor antagonists |
BRPI0411350A (pt) | 2003-06-12 | 2006-07-11 | Hoffmann La Roche | derivados de imidazol substituìdos por heteroarilas como antagonistas de receptores de glutamato |
ATE445399T1 (de) | 2004-03-22 | 2009-10-15 | Lilly Co Eli | Pyridyl-derivate und ihre verwendung als mglu5- rezeptorantagonisten |
US7880009B2 (en) | 2004-05-26 | 2011-02-01 | Eisai R&D Management Co., Ltd. | Cinnamide compound |
DE602005007350D1 (de) * | 2004-06-01 | 2008-07-17 | Hoffmann La Roche | Pyridin-4-yl-ethynylimidazole und -pyrazole als antagonisten des mglu5-rezeptors |
JP4690395B2 (ja) | 2004-06-01 | 2011-06-01 | エフ.ホフマン−ラ ロシュ アーゲー | mGlu5レセプターアンタゴニストとしてのピリジン−4−エチニル−イミダゾール及びピラゾール |
GB0413605D0 (en) * | 2004-06-17 | 2004-07-21 | Addex Pharmaceuticals Sa | Novel compounds |
DE102004044884A1 (de) * | 2004-09-14 | 2006-05-24 | Grünenthal GmbH | Substituierte bizyklische Imidazo-3-yl-amin-Verbindungen |
DE602005019602D1 (de) | 2004-10-26 | 2010-04-08 | Eisai R&D Man Co Ltd | Amorphe form einer zimtsäureamidverbindung |
KR20070106690A (ko) * | 2004-12-27 | 2007-11-05 | 아스트라제네카 아베 | 피라졸론 화합물 및 대사성 글루타메이트 수용체길항제로서 그들의 용도 |
CA2602444C (fr) | 2005-03-23 | 2013-03-19 | F.Hoffmann-La Roche Ag | Derives d'acetylenyl-pyrazolo-pyrimidine comme antagonistes mglur2 |
GB0508319D0 (en) | 2005-04-25 | 2005-06-01 | Novartis Ag | Organic compounds |
CN101309916A (zh) * | 2005-11-18 | 2008-11-19 | 卫材R&D管理有限公司 | 制备肉桂酰胺衍生物的方法 |
EP1953151A4 (fr) * | 2005-11-18 | 2010-06-02 | Eisai R&D Man Co Ltd | Sels de composé cynamide ou solvates de ces derniers |
TWI370130B (en) | 2005-11-24 | 2012-08-11 | Eisai R&D Man Co Ltd | Two cyclic cinnamide compound |
RU2381225C1 (ru) * | 2005-11-24 | 2010-02-10 | Эйсай Ар Энд Ди Менеджмент Ко., Лтд. | Производное циннамида типа морфолина |
WO2007071967A2 (fr) * | 2005-12-19 | 2007-06-28 | The University Of Liverpool | Analgesie |
DE102005062985A1 (de) * | 2005-12-28 | 2007-07-05 | Grünenthal GmbH | Substituierte bis(hetero)aromatische N-Ethylpropiolamide und ihre Verwendung zur Herstellung von Arzneimitteln |
WO2007102580A1 (fr) * | 2006-03-09 | 2007-09-13 | Eisai R & D Management Co., Ltd. | Dérivé polycyclique de cinnamide |
TWI378091B (en) * | 2006-03-09 | 2012-12-01 | Eisai R&D Man Co Ltd | Multi-cyclic cinnamide derivatives |
DE102006011574A1 (de) | 2006-03-10 | 2007-10-31 | Grünenthal GmbH | Substituierte Imidazo[2,1-b]thiazol-Verbindungen und ihre Verwendung zur Herstellung von Arzneimitteln |
US7737141B2 (en) * | 2006-07-28 | 2010-06-15 | Eisai R&D Management Co., Ltd. | Prodrug of cinnamide compound |
UA96970C2 (en) | 2006-12-21 | 2011-12-26 | Ф. Хоффманн-Ля Рош Аг | Polymorphs of a mglur5 receptor antagonist |
TW200848054A (en) | 2007-02-28 | 2008-12-16 | Eisai R&D Man Co Ltd | Two cyclic oxomorpholine derivatives |
JPWO2008140111A1 (ja) * | 2007-05-16 | 2010-08-05 | エーザイ・アール・アンド・ディー・マネジメント株式会社 | シンナミド誘導体のワンポット製造方法 |
WO2009028588A1 (fr) * | 2007-08-31 | 2009-03-05 | Eisai R & D Management Co., Ltd. | Composé polycyclique |
US7935815B2 (en) * | 2007-08-31 | 2011-05-03 | Eisai R&D Management Co., Ltd. | Imidazoyl pyridine compounds and salts thereof |
KR20100107476A (ko) * | 2008-01-28 | 2010-10-05 | 에자이 알앤드디 매니지먼트 가부시키가이샤 | 결정성 신나미드 화합물 또는 그 염 |
US8323805B2 (en) | 2009-06-04 | 2012-12-04 | Nitto Denko Corporation | Emissive aryl-heteroaryl acetylenes |
US8334287B2 (en) | 2009-07-17 | 2012-12-18 | Hoffmann-La Roche Inc. | Imidazoles |
JPWO2012015024A1 (ja) | 2010-07-29 | 2013-09-12 | 大正製薬株式会社 | エチニル−ピラゾール誘導体 |
US8785649B2 (en) | 2010-11-05 | 2014-07-22 | Otsuka Agritechno Co., Ltd. | Ethynylphenylamidine compound or salt thereof, method for producing same, and fungicide for agricultural and horticultural use |
WO2012172093A1 (fr) * | 2011-06-17 | 2012-12-20 | Merz Pharma Gmbh & Co. Kgaa | Dérivé de dihydroindolizine à titre de modulateurs des récepteurs métabotropes de glutamate |
KR101291037B1 (ko) * | 2011-10-12 | 2013-08-01 | 사회복지법인 삼성생명공익재단 | 레스베라트롤 유도체와 스티릴-오각형 방향족 화합물 및 이들의 베타-아밀로이드 플라그에 대한 결합제 및 진단영상제의 용도 |
EP3400220B1 (fr) * | 2016-01-05 | 2021-03-24 | Hua Medicine (Shanghai) Ltd. | Dérivés de pyrazole |
EP3440054B1 (fr) * | 2016-04-06 | 2021-12-01 | Hua Medicine (Shanghai) Ltd. | Dérivés de pyrrole en tant que modulateurs de mglur5 |
UY37557A (es) | 2017-01-10 | 2018-07-31 | Bayer Ag | Derivados heterocíclicos como pesticidas |
AU2018310881C1 (en) | 2017-07-31 | 2021-12-16 | Novartis Ag | Use of mavoglurant in the reduction of cocaine use or in preventing relapse into cocaine use |
CN114746408A (zh) * | 2019-12-02 | 2022-07-12 | 豪夫迈·罗氏有限公司 | 炔基-(杂芳基)-甲酰胺hcn1抑制剂 |
Family Cites Families (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3303199A (en) | 1963-07-15 | 1967-02-07 | Geigy Chem Corp | Certain imidazolone derivatives and process for making same |
US3341548A (en) | 1964-04-29 | 1967-09-12 | Hoffmann La Roche | Nitroimidazoles and their preparation |
DE2035905A1 (de) * | 1970-07-20 | 1972-02-03 | Chemische Fabrik Stockhausen & Cie.,4150Krefeld | Imidazolverbindungen und deren Herstellungsverfahren |
CA1174673A (fr) | 1981-02-27 | 1984-09-18 | Walter Hunkeler | Imidazodiazepines |
US4711962A (en) | 1984-10-18 | 1987-12-08 | Stauffer Chemical Company | Process for selective preparation of ratios of isomers formed on N-substitution of asymmetric imidazoles |
EP0479903B1 (fr) | 1989-06-30 | 1996-02-21 | E.I. Du Pont De Nemours And Company | Imidazoles substitues utiles comme inhibiteurs de l'angiotensin ii |
US5821937A (en) * | 1996-02-23 | 1998-10-13 | Netsuite Development, L.P. | Computer method for updating a network design |
TW544448B (en) * | 1997-07-11 | 2003-08-01 | Novartis Ag | Pyridine derivatives |
YU6100A (sh) * | 1997-08-14 | 2002-10-18 | F.Hoffmann-La Roche Ag. | Heterociklični viniletri protiv neuroloških poremećaja |
US6377987B1 (en) * | 1999-04-30 | 2002-04-23 | Cisco Technology, Inc. | Mechanism for determining actual physical topology of network based on gathered configuration information representing true neighboring devices |
EP1214303A1 (fr) * | 1999-08-31 | 2002-06-19 | Merck & Co., Inc. | Composes heterocycliques et procedes d'utilisation de ceux-ci |
-
2001
- 2001-11-26 JP JP2002547905A patent/JP4077317B2/ja not_active Expired - Fee Related
- 2001-11-26 AU AU2956702A patent/AU2956702A/xx active Pending
- 2001-11-26 EP EP01990437A patent/EP1349839B8/fr not_active Expired - Lifetime
- 2001-11-26 WO PCT/EP2001/013714 patent/WO2002046166A1/fr active IP Right Grant
- 2001-11-26 ES ES01990437T patent/ES2248410T3/es not_active Expired - Lifetime
- 2001-11-26 IL IL15599901A patent/IL155999A0/xx unknown
- 2001-11-26 AT AT01990437T patent/ATE288898T1/de active
- 2001-11-26 PL PL01366222A patent/PL366222A1/xx unknown
- 2001-11-26 MX MXPA03004862A patent/MXPA03004862A/es active IP Right Grant
- 2001-11-26 CA CA002430696A patent/CA2430696C/fr not_active Expired - Fee Related
- 2001-11-26 HU HU0400570A patent/HUP0400570A3/hu unknown
- 2001-11-26 CN CNB018199933A patent/CN1257894C/zh not_active Expired - Fee Related
- 2001-11-26 DK DK01990437T patent/DK1349839T3/da active
- 2001-11-26 RS YU43903A patent/RS43903A/sr unknown
- 2001-11-26 DE DE60108900T patent/DE60108900T2/de not_active Expired - Lifetime
- 2001-11-26 PT PT01990437T patent/PT1349839E/pt unknown
- 2001-11-26 NZ NZ525917A patent/NZ525917A/en unknown
- 2001-11-26 SI SI200130304T patent/SI1349839T1/xx unknown
- 2001-11-26 KR KR10-2003-7007421A patent/KR100515549B1/ko not_active IP Right Cessation
- 2001-11-26 BR BR0115871-6A patent/BR0115871A/pt not_active Application Discontinuation
- 2001-11-26 AU AU2002229567A patent/AU2002229567B2/en not_active Ceased
- 2001-11-26 SK SK840-2003A patent/SK8402003A3/sk unknown
- 2001-11-26 CZ CZ20031795A patent/CZ20031795A3/cs unknown
- 2001-11-26 RU RU2003119548/04A patent/RU2284323C9/ru not_active IP Right Cessation
- 2001-11-28 US US09/996,641 patent/US6706707B2/en not_active Expired - Fee Related
- 2001-12-03 AR ARP010105602A patent/AR035401A1/es unknown
-
2003
- 2003-03-25 US US10/396,172 patent/US6972299B2/en not_active Expired - Fee Related
- 2003-04-04 US US10/407,929 patent/US6927232B2/en not_active Expired - Fee Related
- 2003-05-19 ZA ZA200303870A patent/ZA200303870B/en unknown
- 2003-05-19 IL IL155999A patent/IL155999A/en not_active IP Right Cessation
- 2003-05-26 HR HR20030429A patent/HRP20030429A2/hr not_active Application Discontinuation
- 2003-06-03 NO NO20032503A patent/NO324326B1/no not_active IP Right Cessation
- 2003-06-03 EC EC2003004640A patent/ECSP034640A/es unknown
- 2003-06-04 MA MA27192A patent/MA26971A1/fr unknown
- 2003-06-04 BG BG107877A patent/BG107877A/bg unknown
-
2004
- 2004-08-13 HK HK04106082A patent/HK1063318A1/xx not_active IP Right Cessation
-
2005
- 2005-01-18 US US11/037,904 patent/US20050131043A1/en not_active Abandoned
-
2007
- 2007-12-17 JP JP2007325072A patent/JP2008169206A/ja active Pending
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AU2956702A (en) | Phenylethenyl or phenylethinyl derivatives as glutamate receptor antagonists | |
HK1076459A1 (en) | 4-Phenyl-pyridine derivatives as neurokinin-1 receptor antagonists | |
PL365377A1 (en) | Amide derivatives as nmda receptor antagonists | |
HK1058361A1 (en) | Urea derivatives as integrin alpha 4 antagonists | |
HK1046909B (zh) | 做為5-ht1b拮抗劑的哌嗪衍生物 | |
AU8200501A (en) | 4-phenyl-pyridine derivatives as neurokinin-1 receptor antagonists | |
PL356990A1 (en) | Isoxazolecarboxamide derivatives as alpha1-adrenergic receptor antagonists | |
MXPA03006991A (es) | Derivados de piperidina como antagonistas de neurocinina 1. | |
IL148623A0 (en) | Thienoisoxazolyl-and thienylpyrazolyl-phenoxy substituted propyl derivatives useful as d4 antagonists | |
IL144299A0 (en) | N-triazolymethyl-piperazine derivatives as neurokinin receptor antagonists | |
HK1045684A1 (en) | Biphenyl derivatives as antagonists of the neurokinine-1 receptor. | |
DE50008020D1 (de) | Substituierte pyrrolidin-2,3,4-trion-derivate wirksam als nmda-rezeptor-antagonisten | |
ATE338043T1 (de) | 5-methoxy-8-aryl- 1,2,4ötriazolo 1,5-aöpyridine derivative als adenosin-rezeptor antagonisten | |
IL150272A0 (en) | Indole derivatives as mcp-1 receptor antagonists | |
EG24179A (en) | Vitronectin receptor antagonists | |
EP1169042A4 (fr) | Derives de la dibenzo-azepine en tant qu'antagonistes du recepteur alpha v integrine | |
IL160093A0 (en) | Novel imidazolidine derivatives, their preparation and their use as vla-4 antagonists | |
SI1383750T1 (sl) | Derivati uree kot integrin alfa 4 antagonisti |